Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database

The journal of headache and pain 2022 May 3;23(1):53 doi: 10.1186/s10194-022-01424-w. Alexandre O Gérard, Diane Merino, Elise K Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet, Milou-Daniel Drici Abstract Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide

Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies

Current Medical Research and Opinion 2022 May 13;1-18 doi: 10.1080/03007995.2022.2076475. Online ahead of print. Serge Perrot, Alain Eschalier, Jules Desmeules, Michel Lanteri-Minet, Nadine Attal Abstract Background: Paracetamol is the commonest analgesic worldwide in primary care. Despite evidence-based recommendations for management of acute and chronic